Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy
Recruiting
A5422 is a phase 1, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and immunogenicity of a vaccination with stabilized CH505 TF chTrimer admixed with 3M-052-AF + Aluminum hydroxide (Alum), to assess the effect of CH505 TF chTrimer vaccine as a therapeutic vaccine in adults living with HIV-1 on suppressive antiretroviral therapy (ART) with the aim of inducing new HIV-1 Envelope (Env) B-cell neutralizing immune responses. Participants will be on stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: University of California, Los Angeles CARE Center CRS, Los Angeles, California +24 locations
Conditions: HIV-1
Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)
Recruiting
A Double-Masked, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of d-MAPPS™ Ophthalmic Solution in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGHVD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Beverly Hills Institute of Ophthalmology, Beverly Hills, California +4 locations
Conditions: OGHVD
Assessment Intravenous Site Events During Outpatient Infusion Procedures With a Wireless Thermal Measurement Device During
Recruiting
This study evaluates a Non-invasive Thermal Infusion Site Monitor (NTISM) device when used during routine outpatient infusion treatments.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/29/2025
Locations: Infusacare, Skokie, Illinois
Conditions: IV Infiltration, IV Extravasation
Cell Free DNA in Cardiac Sarcoidosis
Recruiting
Sarcoidosis is a multisystem granulomatous disease of unknown cause that can affect any organ in the body, including the heart. Granulomatous myocarditis can lead to ventricular dysfunction and ventricular arrhythmias causing significant morbidity and mortality. Immunosuppressive therapy (IST) has been shown to reverse active myocarditis and preserve left ventricular (LV) function and in some cases improve LV function. In addition, IST can suppress arrhythmias that develop due to active myocardi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: University of Iowa, Iowa City, Iowa +1 locations
Conditions: Sarcoidosis With Myocarditis, Sarcoidosis, Healthy, ST Elevation Myocardial Infarction
Suicide Intervention for Alaska Native Youth
Recruiting
Two interventions will be delivered virtually to American Indian/Alaska Native youth who have been hospitalized with suicidal attempt, suicidal ideation, or associated risk behaviors, including alcohol-related injury.
Gender:
ALL
Ages:
Between 14 years and 24 years
Trial Updated:
05/29/2025
Locations: Yukon-Kuskokwim Health Corporation, Bethel, Alaska +1 locations
Conditions: Suicide, Attempted, Suicidal Ideation, Alcohol Intoxication, Alaska Native Youth Aged 14 - 24
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Recruiting
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Research Site, Birmingham, Alabama +60 locations
Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Sevoflurane's Effect on Neurocognition Study
Recruiting
The purpose of this study is to determine the effects of acute pain on long-term memory and conditioned physiologic responses in the presence and absence of low dose sevoflurane. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena. The study will occur over 2 visits and involves no long-term follow up.
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
05/29/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Anesthesia, Pain, Amnesia
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
05/29/2025
Locations: Research Site, Duarte, California +11 locations
Conditions: Metastatic Prostate Cancer
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Recruiting
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +10 locations
Conditions: Prostate Cancer
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Recruiting
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona +19 locations
Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
Recruiting
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors an... Read More
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
05/29/2025
Locations: VYGR Site 840018, Los Angeles, California +24 locations
Conditions: Alzheimer's Disease (AD)
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
Recruiting
The goal of this pilot study is to determine the feasibility of a randomized trial of the YES-CAN! (Youth Engaged Strategies to Change Adolescent Norms) program to prevent nicotine vaping among adolescents. The program integrates the following evidence-based strategies: youth-adult collaboration; youth-developed narrative videos to convey health messages; peer leaders as change agents; and sustained implementation to change the normative environment. Two middle/high school communities will recei... Read More
Gender:
ALL
Ages:
Between 9 years and 89 years
Trial Updated:
05/29/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Nicotine Vaping